Is there any Indian generic version of Adagrasib (Krazati) and comparison of versions in various countries?

As a new type of KRAS G12C inhibitor, adagrasib (Krazati) currently has limited market availability globally. First of all, it needs to be made clear that as of now, no Indian version of the generic drug has been approved for marketing, so patients cannot obtain the drug through generic channels in the Indian market. This means that the Indian market still relies on the original drug or the supply through formal channels in other countries. The price is relatively high and it is difficult to obtain.

In the international market, adagrasib is mainly sold as an original drug. The American version of the original drug is very expensive, with each box costing up to hundreds of thousands of yuan, which is a considerable financial burden for most patients. The advantage of original American drugs is that they have undergone strict clinical trials and quality control. The ingredients and efficacy of the drugs are reliable, and they are suitable for patients who need to ensure the safety and efficacy of medication.

In comparison, some overseas markets provide Lao version of generic drugs, which are relatively cheap, about more than 3,000 yuan per box. The ingredients of these generic drugs are basically the same as those of the original drugs, but the prices are significantly lower, allowing patients with limited economic conditions to obtain treatment opportunities to a certain extent. However, it should be noted that when patients choose to purchase drugs across borders, they should ensure that they purchase through formal channels to avoid the risk of unstable quality or counterfeit drugs.

Taken together, adagrasibu currently exists mainly in the global market in two forms: the US original drug and the Laotian generic drug. There are no generic drugs on the market in India yet, and the domestic market has not yet been opened, so Chinese patients can only obtain them through overseas channels. For patients, they should choose a suitable drug version based on their own economic conditions, disease progression and doctor's guidance. At the same time, they should pay attention to regular drug purchase channels and drug quality to ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/